Golden Age of Gaia

Toward a World that Works for Everyone

Menu
  • Home
    • About The Staff
    • FAQs
    • Glossary
    • Privacy Policy
    • Terms of Service
    • Downloads Page
    • Close
  • Contact Us
  • Commentary
    • Charlie
    • Kat
    • Kathleen Mary Willis
    • Narendra Mishra
    • Sitara
    • Steve Beckow
    • Suzanne Maresca
    • Writer’s Corner
    • Close
  • News
    • Ascension
    • Accountability
    • Building Nova Earth
    • Channelings/Commentary
    • Reval/GCR/Stewardship/Abundance
    • Homelessness
    • InLight Universal Shows
    • New Maps of Heaven
    • Opioid Crisis
    • Politics
    • Spirituality
    • Close
  • Library/Archives
  • Hope Chest
    • Hope Chest: Frequently Asked Questions
    • Close
  • Forums
/ Home / Issue Mediation Process R3 / Accountability / Big Pharma and Pandemics / Big Pharma Promotes Illegal “Off-Label” Drug Uses
post

Big Pharma Promotes Illegal “Off-Label” Drug Uses

Print Friendly, PDF & Email

When Drug Makers’ Profits Outweigh Penalties

By David Evans

Washington Post

Originally Published in Bloomberg News

Sunday, March 21, 2010; G01

https://www.washingtonpost.com/wp-dyn/content/article/2010/03/19/AR2010031905578.html

On the morning of Sept. 2, 2009, another Pfizer unit, Pharmacia & Upjohn, agreed to plead guilty to the same crime. This time, Pfizer executives had been instructing more than 100 salespeople to promote Bextra — a drug approved only for the relief of arthritis and menstrual discomfort — for treatment of acute pain of all kinds.

For this new felony, Pfizer paid the largest criminal fine in U.S. history: $1.19 billion. On the same day, it paid $1 billion to settle civil cases involving the off-label promotion of Bextra and three other drugs with the United States and 49 states.

“At the very same time Pfizer was in our office negotiating and resolving the allegations of criminal conduct in 2004, Pfizer was itself in its other operations violating those very same laws,” Loucks, 54, says. “They’ve repeatedly marketed drugs for things they knew they couldn’t demonstrate efficacy for. That’s clearly criminal.”

The penalties Pfizer paid for promoting Bextra off-label were the latest chapter in the drug’s benighted history. The FDA found Bextra to be so dangerous that Pfizer took it off the market for all uses in 2005.

Across the United States, pharmaceutical companies have pleaded guilty to criminal charges or paid penalties in civil cases when the Justice Department finds that they deceptively marketed drugs for unapproved uses, putting millions of people at risk of chest infections, heart attacks, suicidal impulses or death.

It used to be legal for companies to promote drugs in the United States for any use. Congress banned the practice in 1962, requiring pharmaceutical companies to first prove their drugs were safe and effective for specific uses.

If the law is clear, why do drug companies keep breaking it? The answer lies in economics. Pharmaceutical companies spend about $1 billion to develop and test a new drug. To recoup their investment, the companies want doctors to prescribe their drugs as widely as possible.

Since May 2004, Pfizer, Eli Lilly, Bristol-Myers Squibb and four other drug companies have paid a total of $7 billion in fines and penalties. Six of the companies admitted in court that they marketed medicines for unapproved uses. In September 2007, New York-based Bristol-Myers paid $515 million — without admitting or denying wrongdoing — to federal and state governments in a civil lawsuit brought by the Justice Department. The six other companies pleaded guilty in criminal cases.

In January 2009, Indianapolis-based Lilly, the largest U.S. psychiatric drugmaker, pleaded guilty and paid $1.42 billion in fines and penalties to settle charges that it had for at least four years illegally marketed Zyprexa, a drug approved for the treatment of schizophrenia, as a remedy for dementia in elderly patients.

In five company-sponsored clinical trials, 31 people out of 1,184 participants died after taking the drug for dementia — twice the death rate for those taking a placebo, according to an article in the Journal of the American Medical Association.

“Marketing departments of many drug companies don’t respect any boundaries of professionalism or the law,” says Jerry Avorn, a professor at Harvard Medical School. “The Pfizer and Lilly cases involved the illegal promotion of drugs that have been shown to cause substantial harm and death to patients.”

The widespread off-label promotion of drugs is yet another manifestation of a health-care system that has become dysfunctional.

“It’s an unbearable cost to a system that’s going broke,” Avorn says. “We can’t even afford to pay for effective, safe therapies.”

About 15 percent of all U.S. drug sales are for unapproved uses without adequate evidence the medicines work, according to a study by Randall Stafford, a medical professor at Stanford University.

As large as the penalties are for drug companies caught breaking the off-label law, the fines are tiny compared with the firms’ annual revenue.

The $2.3 billion in fines and penalties Pfizer paid for marketing Bextra and three other drugs cited in the Sept. 2 plea agreement for off-label uses amount to just 14 percent of its $16.8 billion in revenue from selling those medicines from 2001 to 2008.

The total of $2.75 billion Pfizer has paid in off-label penalties since 2004 is a little more than 1 percent of the company’s revenue of $245 billion from 2004 to 2008.

Lilly already had a criminal conviction for misbranding a drug when it broke the law again in promoting schizophrenia drug Zyprexa for off-label uses beginning in 1999. The medication provided Lilly with $36 billion in revenue from 2000 to 2008. That’s more than 25 times as much as the total penalties Lilly paid in January.

Companies regard the risk of multimillion-dollar penalties as just another cost of doing business, says Lon Schneider, a professor at the University of Southern California’s Keck School of Medicine in Los Angeles. In 2006, he led a study for the National Institute of Mental Health of off-label use of drugs, including Zyprexa.

“There’s an unwritten business plan,” he says. “They’re drivers that knowingly speed. If stopped, they pay the fine, and then they do it again.”

Paying the doctors

In pushing off-label use of drugs, companies find ready and willing partners in physicians. Under the fragmented system of U.S. medical regulation, it’s legal for doctors to prescribe FDA-approved drugs for any use. The FDA has no authority over doctors, only over drug companies, regarding off-label practices. It’s up to the states to oversee physicians.

“I think the physician community has to take some ownership responsibility and do their own due diligence beyond the sales and marketing person,” says Boston’s former U.S. Attorney Michael Sullivan.

Doctors generally don’t tell people they’re prescribing drugs pitched to them by pharmaceutical salespeople for unapproved treatments, says Peter Lurie, former deputy medical director of Public Citizen, a Washington-based public interest group. Most doctors don’t keep track of FDA-approved uses of drugs, he says.

“The great majority of doctors have no idea; they don’t even understand the distinction between on- and off-labeling,” he says.

Pfizer’s marketing program offered doctors up to $1,000 a day to allow a Pfizer salesperson to spend time with the physician and his patients, according to a whistle-blower lawsuit filed by John Kopchinski, who worked as a salesman at Pfizer from 1992 to 2003.

“By ‘pairing up’ with a physician, the sales representative was able to promote over a period of many hours, without the usual problems of gaining access to prescribing physicians,” Kopchinski says. “In essence, this amounted to Pfizer buying access to physicians.”

Pfizer spokesman Chris Loder says the company stopped what it calls “mentorships” in 2005. He says Pfizer paid doctors $250 a visit. The goal was clear: Get doctors to prescribe a new drug as widely as possible.

Pfizer’s Neurontin is a case in point. The FDA approved the drug as a supplemental medication to treat epilepsy in 1993. Pfizer took in $2.27 billion from sales of Neurontin in 2002. A full 94 percent — $2.12 billion — of that revenue came from off-label use, according to the prosecutors’ 2004 Pfizer sentencing memo.

Since 2004, companies that are now Pfizer divisions have pleaded guilty to off-label marketing of two drugs. Pfizer continued off-label promotions for these medications after buying the firms, according to documents.

Pfizer first stepped into an off-label scheme in 1999, when it offered to buy Warner-Lambert, based in New Jersey. Prosecutors charged that Warner-Lambert marketed Neurontin off-label between 1995 and 1999.

Warner-Lambert admitted doing so for one year in a May 2004 guilty plea for which Pfizer paid $430 million in fines and penalties.

When the FDA approved Neurontin in 1993 to be used only along with other epilepsy drugs, the agency wrote that as a side effect, the drug can induce depression and suicidal thoughts in patients.
The whistle-blower

Much of what prosecutors learned about Warner-Lambert’s marketing of Neurontin comes from a former employee, David Franklin, who holds a Ph.D. in microbiology.

Franklin, 48, whose title at Warner-Lambert was medical liaison, says his job involved more salesmanship than science. He told doctors that Neurontin was the best drug for a dozen off-label uses, including pain relief, bipolar disease and depression.

“Technically, I had responsibility for answering physician questions about all of Parke-Davis’s drugs,” Franklin says. “In practice, my real job was to promote Neurontin for off-label indications heavily — to the exclusion of just about everything else.”

Franklin says he knew such uses of the drug had no scientific support for effectiveness and safety.

“I was actually undermining their ability to fulfill the Hippocratic oath,” Franklin says, referring to a physician’s pledge to “First, do no harm.”

After working for Warner-Lambert for three months, Franklin quit and filed a whistle-blower lawsuit on behalf of taxpayers to recover money the government paid for illegally promoted drugs. He stood to collect as much as 30 percent of any settlement the company made with the government.

Franklin had to wait four years — until 2000 — before the Justice Department began a criminal investigation. In November 1999, Pfizer made its public offer to buy Warner-Lambert. In January 2000, a federal grand jury in Boston issued subpoenas to Warner-Lambert employees to testify about the marketing of Neurontin.

That March, Warner-Lambert’s annual report disclosed that prosecutors were building a criminal case. Undeterred, Pfizer bought Warner-Lambert in June for $87 billion — the third-largest merger in U.S. history.
More sales than Viagra

A year after the acquisition, the FDA discovered that Neurontin was still being marketed off-label. In a June, 2001 letter to the company, the agency wrote that Pfizer’s promotion of the drug “is misleading and in violation of the Federal Food, Drug and Cosmetics Act.”

Pfizer marketed Neurontin off-label after receiving that letter, agency records show. For 2001, Pfizer reported revenue of $1.75 billion from Neurontin sales, making it the company’s fourth-largest-selling drug that year, ahead of impotence pill Viagra, which Neurontin topped for four years.

As Neurontin sales soared to $2.27 billion in 2002, the FDA found that Pfizer was improperly claiming that the drug was useful for a broader range of brain disorders than scientific evidence had established.

The agency sent a letter dated July 1, 2002, that said the company’s marketing practices were in violation of FDA rules. It asked Pfizer to stop using misleading promotions. Pfizer reported $2.7 billion in revenue from Neurontin in 2003. Overall, the drug has provided Pfizer with $12 billion in revenue.

Pfizer spokesman Chris Loder says, “Regarding the 2001 and 2002 FDA letters, we do not believe that they were suggestive of any continuing off-label promotion.”

For blowing the whistle on his employer, Franklin collected $24.6 million under the False Claims Act.

Prosecutors Loucks and Sullivan got involved in the case after Franklin filed his suit, relying on information from Franklin and their own investigation. Before 2004, prosecutions for off-label marketing were rare.

“Until a couple of these cases became public, companies were probably saying, ‘Everybody does it this way,’ ” Sullivan says.

Loucks had a track record in off-label prosecutions. In 1994, he negotiated a $61 million settlement with C.R. Bard of New Jersey, which pleaded guilty to promoting off-label use of a heart catheter that led to patient deaths.

The off-label campaign

In the January 2004 settlement negotiations with Loucks, Sullivan and two other prosecutors, Pfizer’s lawyers assured the U.S. Attorney’s Office that the company wouldn’t market drugs off-label.

“They asserted that the company understood the rules and had taken steps to assure corporate compliance with the law,” Loucks says. “We remember those promises.”

What Pfizer’s lawyers didn’t tell the prosecutors was that Pfizer was at that moment running an off-label marketing promotion using more than 100 salespeople who were pitching Bextra, according to a Pfizer sales manager who pleaded guilty to misbranding a drug in March 2009.

Pharmacia & Upjohn developed Bextra, which was approved by the FDA in 2001 for only the treatment of arthritis and menstrual discomfort.

P&U and Pfizer had by then crafted a joint marketing agreement to sell the drug. In November 2001, Mary Holloway, a Pfizer Northeast regional manager, began illegally training and directing her sales team to market Bextra for the relief of acute pain, Holloway admitted in the plea.

On Dec. 4, 2001, Pfizer executives sent Holloway a copy of a nonpublic FDA letter to the company. The agency had denied Pfizer’s application to market Bextra for acute pain. Clinical trials had shown Bextra could cause heart damage and death.

Pfizer bought Pharmacia & Upjohn in April 2003. From 2001 through 2003, P&U, first as an independent company and then as a unit of Pfizer, paid doctors more than $5 million in cash to lure them to resorts, where salespeople illegally pitched off-label uses for Bextra, P&U admitted.

In her guilty plea, Holloway said her team had solicited hospitals to create protocols to buy Bextra for the unapproved purpose of acute pain relief. Her representatives didn’t mention the increased risk of heart attacks in their marketing.

They told doctors that side effects were no worse than those of a sugar pill, Holloway said.

In 2003, Holloway reported her unit’s off-label promotions of Bextra up the corporate ladder at Pfizer, according to a presentencing memo to the judge written by Robert Ullmann, Holloway’s attorney. Top managers didn’t attempt to halt the illegal conduct, the memo said.

By late 2004, Bextra reached blockbuster status, with annual sales of $1.29 billion. Holloway promoted Bextra until the FDA asked Pfizer in April 2005 to pull it from the market for all uses.

The agency concluded that the drug increased the risk of heart attacks, chest infections and strokes in cardiac surgery patients. In June 2009, Holloway, 47, was sentenced to two years on probation and fined $75,000. She didn’t return phone calls seeking comment.

‘We regret . . . ‘

By 2007, the criminal and civil cases against Pfizer, its employees and its subsidiaries had begun to mount. The tally of drugs cited by federal prosecutors for off-label promotion reached six by 2009. In April 2007, P&U pleaded guilty to a felony charge of offering a $12 million kickback to a pharmacy benefit manager. Pfizer paid a criminal fine of $19.7 million. In September 2009, Pfizer agreed to pay $2.2 billion in fines and penalties. P&U pleaded guilty to a felony charge of misbranding Bextra with the intent to defraud. After the settlement, Pfizer general counsel Amy Schulman said the company had learned its lesson.

“We regret certain actions we’ve taken in the past,” she said. “Corporate integrity is an absolute priority for Pfizer.”

One reason drug companies keep breaking the law may be because prosecutors and judges have been unwilling to use the ultimate sanction — a felony conviction that would exclude a company from selling its drugs for reimbursement by state health programs and federal Medicare.

At Pfizer’s Pharmacia sentencing in October, U.S. District Court Judge Douglas Woodlock said companies don’t appear to take the law seriously. “It has become something of a cost of doing business for some of these corporations, to shed their skin like certain animals and leave the skin and move on,” he said.

As prosecutors continue to uncover patterns of deceit in off-label marketing, millions of patients across the nation remain in the dark. Doctors often choose the medications based on dishonest marketing by drug company salesmen.

Loucks says that putting an end to the criminal off-label schemes will be difficult. As drugmakers repeatedly plead guilty, they’ve shown they’re willing to pay hundreds of millions of dollars in fines as a cost of generating billions in revenue.

The best hope, Loucks says, is that drug companies actually honor the promises they keep making — and keep breaking — to obey the law of the land.

As much as $100 million for health-care fraud enforcement is tied up in the stalled reform legislation, according to Loucks.

“It will be increasingly hard for the threat of exclusion to seem credible and thus serve as a deterrent to bad corporate behavior,” he says, “unless Congress supports health-care fraud prosecutions with more money.”

A version of this story originally appeared in Bloomberg Markets Magazine. It was awarded a 2010 Society of American Business Editors and Writers award for enterprise reporting and general excellence.

Share

Subscribe to the Golden Age of Gaia

Recent Posts

  • The Significance of the Torus
  • Sending Love Tuesdays — July 5th Zoom — 5pm PST / 8pm EST
  • Celia Fenn: July is Sirius Season
  • The 9D Arcturian Council Through Daniel Scranton: Get Pulled Up & In by Our Tractor Beam
  • Judith Kusel: Become Fluid
  • Dr Schavi ~ Major Cosmic Forces Intensification Report
  • Saul Through John: July 4th Message
  • This Fourth of July: We Will Get Through
  • The Best Party We Never Went To
  • Stop. Just Stop

Archives

Collective Meditation: Sending LOVE Tuesdays — 5-5:30pm PST / 8-8:30pm EST

Holding Love and Sending Love

Click on Graphic

Austria Scraps Vaccine Mandate

Russell L. Blaylock: Covid Update: What is the Truth?

Jesus Through John: There are no Accidents

 

2000 Mules

“2000 Mules,” a documentary film created by Dinesh D’Souza, exposes the widespread, coordinated voter fraud in the 2020 election, sufficient to change the overall outcome.

Matthew Ward on Virus, Vaccine, and 5G

Archbishop Vigano Calls for Anti-Globalist Alliance

Former Premier Calls Vaccine Actions Callous and Unconstitutional

Hit graphic to go to story

1969 Doctors and Health Professionals: End all CV19 Measures

Graphene Hydroxide and the Transhumanist Agenda

https://goldenageofgaia.com/wp-content/uploads/2021/12/LEAKED-22Project-Pandora22-Multiple-Presidents-KILLED-to-Keep-this-HIDDEN.mp4

Dr. Peter McCullough: Let’s Win the War Against Therapeutic Nihilism

Vaccines are Making It Worse, Not Better

Tap on graphic or go here.

An Open Letter to the Unvaccinated

12 Questions – An Open Letter from BC Healthcare Professionals Looking For Answers

Adamu Declares Victory

Everything you wanted to know about the virus and vaccine, the New World Order and their future from Adamu through Zingdad. Definitely a keeper.

The Cabal’s Game Plan: The Covid Action Platform

Election Fraud Explained

  • Mike Lindell’s Absolute Proof of election fraud

Declaration of the People of the United States for Global Peace and Prosperity

Do not venture where there is no love. Because, if there is no love, then there is no truth. And if there is no truth, there will not be peace and [peace], Sweet One, is the Plan. (Archangel Michael, Personal Reading, June 17, 2020.)

All of life is embarked on the same journey – from God to God – a voyage of Self-discovery

The Pattern of the Mother

  • This universe is designed around the pattern of the Divine Mother. What is that pattern?
  • Creation, preservation, transformation = love building, love preserving, love dissolving = inbreath, pause, outbreath = rajas, sattwa, thamas (gunas) = Akar, Ukar, Makar (Aum) = Brahma, Vishnu, Shiva (Trimurthy).

Spiritual Advice in Troubled Times

  • The Arcturian Group explains….

How Do I Make Sense of Our World?

The best introduction to the subject in recent memory.

The Question of Sending Love and Light


Can sending love and light be harmful?

Reassurance for Those Who Feel Disturbed by the Cabal’s Plan

rabbit-hole

There is a Plan

There will be no world war. No nuclear devices can be exploded in space. Global martial law is to restore law and order worldwide. There is a Plan.

No War for the World

Trust the Plan! St. Germain through James McConnell

Click on graphic

Canadian Freedom Convoy 1

https://goldenageofgaia.com/wp-content/uploads/2022/02/Cities-across-Canada-join-the-movement-1.mp4

Canadian Freedom Convoy 2

https://goldenageofgaia.com/wp-content/uploads/2022/02/telegram-cloud-document-1-4915997293301204030-1-1.mp4

Please support this site. Donate:


A 501(c)(3) tax-exempt non-profit
  • Building, anchoring, and restoring hope, trust and Love within the human community.
  • "The key to Love is sharing, ... [balancing] give and receive." - The Divine Mother.

Downloads Page

(Always) free introductory texts on Ascension, Disclosure, Abundance, and Accountability. Especially of interest to those new to these subjects.

For your daily news, join Suzi on Buy Me a Coffee!

 

  • Dynamic times and rampant internet censorship brought me to create a new outlet for the unending flow of information.
  • Information is Light. Seeking information is Light Work.
  • My news site link ~ https://www.buymeacoffee.com/SuzanneMaresca.

Kathleen: A Door to Everything/Voice of Freedom

  • Welcome to my two websites, A Door to Everything and Voice of Freedom, the first about volunteering with women in recovery and the second about how things work in the higher realms.
  • I offer Online Card Readings, Zoom Meditation and Classes on How Things Work in the Higher Realms, Tuesdays, Wednesdays, & Fridays. See GAoG or VoF for class links.

Spiritual Counselling

  • Releasing old patterns of limitation.
  • Remembering, embodying, and expressing your true Self

Len Satov
SourceLight – Seeing you home
http://www.lensatov.com/

HB & AHWAA Transcripts & Audios: Divine Beings, Universal Laws, Blessings & Virtues

* HB/AHWAA Transcripts and Audiotapes

* On the Importance of the Universal Laws

* The Universal Law: What, How, and Why?

Lightworker Links


Our recommendations on other lightworker sites.

Alternative News of the World

Our recommendations on other constructive news sites.

What is the Purpose of Life?


Click on graphic

The Mother’s Clarion Call to All of Humanity!

This is my clarion call to all of humanity to embrace love, to embrace truth, to embrace peace…

The Divine Mother’s Mandate

Build what is divinely beautiful. I give you my divine authority to do so. I will guide you. I will help you. But I entrust this to you as well. …

  • We are helping you. That gateway is open and you are being flooded and you are being assisted and you will be assisted every step of the way.
  • – “Transcript ~ The Divine Mother: Take Up Your Divine Authority, AHWAA, February 23, 2017,” February 28, 2017.
  • On the Divine Plan for Ascension.

Archangel Michael: Lead or Leave a Vacuum


If no [lightworker] steps forward into [leadership] ...

Archangel Michael: Do not Get Caught in the Drama of White Hats or Black Hats

  • Beloved ones, do not allow yourselves to be distracted, yes, by the chaos….
  • Do not get caught in the drama of white hats or black hats, or good guys or bad guys. All beings are birthed directly from the Heart of One…. (“Archangel Michael: Do not Get Caught in the Drama of White Hats or Black Hats,” Nov. 12, 2019; see here.

Ronna Vezane ~ Archangel Michael’s Gift: New Age Creed

Werner Erhard on Responsibility

“Responsibility begins with the willingness to take the stand that one is cause in the matter of one’s life. It is a declaration not an assertion, that is, it is a context from which one chooses to live. Responsibility is not burden, fault, praise, blame, credit, shame or guilt. In responsibility, there is no….”  (Read more…)

The Declaration of Human Freedom

Site Resources

Have a question about Ascension? Disclosure? The Galactics? Prosperity? Enlightenment? Life after death?

All site resources can be viewed here.

Important Videos and Documents


(As of Dec. 2021)

Arcturian Sacred Geometry

Mission Statement of the Golden Age of Gaia

On a Personal Note

  • I’m neither qualified to be a spiritual teacher nor do I wish to be one.
  • I’m a writer who wishes to share his views with you on subjects of mutual interest and listen to yours as lightworker equals and spiritual adults.

eBooks

  • The Importance of Disclosure
  • Accountability
  • The Coming of the Golden Age
  • Spiritual Essays
  • Spiritual Evolution is the Divine Plan for Life

GAoG Wiki Links

  • First Contact
  • New Maps of Heaven
  • From Darkness Unto Light
  • Other Dictionaries of Enlightenment

Downloads Page

Downloads of all books by Golden Age of Gaia authors (all are free)

User Info

  • Contact Us
  • Terms of Service
  • Privacy Policy

Copyright © 2022 The Golden Age Of Gaia

Copyright © 2022 · Dynamik-Gen on